異位性皮膚炎臨床試驗市場- 按分子類型（大、小）、研究設計（介入性、觀察性）、階段（I、II、III、IV）、模式（外包、內部）、產業（製藥和生物科技公司、 CRO），2024 - 2032 年全球預測

Atopic Dermatitis Clinical Trials Market - By Molecule Type (Large, Small), Study Design (Interventional, Observational), Phase (I, II, III, IV), Mode (Outsourced, In-house), Industry (Pharma & Biotech Companies, CRO's), Global Forecast 2024 - 2032

出版日期: 2024年03月14日 | 出版商:

Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在該領域臨床試驗和研發不斷增加的推動下，2024 年至 2032 年間，全球異位性皮膚炎臨床試驗市場規模的複合年成長率將達到 11.4%。隨著全球異位性皮膚炎盛行率的上升，製藥公司、研究機構和醫療保健提供者正在加緊努力開發創新療法和療法。例如，2024年4月，處於臨床階段的生物製藥公司Corvus Pharmaceuticals, Inc.宣布啟動soquelitinib的1期臨床試驗。這項隨機、安慰劑對照、雙盲試驗將評估索奎替尼對中度至重度異位性皮膚炎患者的療效。

這些臨床試驗旨在評估新藥、生物製劑和局部治療對異位性皮膚炎患者的療效、安全性和耐受性。此外，對該疾病潛在機制的了解的進步正在推動新治療標靶的探索。因此，對參與者、研究設施和專業服務的需求不斷成長，擴大了對異位性皮膚炎臨床試驗的需求並推動市場向前發展。

整個異位性皮膚炎臨床試驗產業根據研究設計、分子類型、階段、模式、產業和地區進行分類。

小分子細分市場將在2024年至2032年經歷嚴格的發展。憑藉小分子的多功能性和針對性方法，製藥公司擴大將研究重點放在開發異位性皮膚炎的創新療法上。與傳統療法相比，這些分子具有提高療效和減少副作用的潛力，從而推動了臨床試驗的興趣和投資。隨著對有效和更安全治療的需求不斷成長，臨床試驗中小分子的探索仍然是推進異位性皮膚炎治療領域的關鍵驅動力。

從2024 年到2032 年，觀察性研究領域的異位性皮膚炎臨床試驗市場佔有率將出現顯著的複合年成長率。關重要的作用。透過補充傳統的臨床試驗，觀察性研究為異位性皮膚炎治療的長期有效性和安全性提供了有價值的見解。製藥公司和研究人員越來越認知到觀察資料的重要性，推動了進行此類研究的投資和興趣，以滿足患者和醫療保健提供者在治療異位性皮膚炎方面不斷變化的需求。

亞太地區異位性皮膚炎臨床試驗市場將在 2024 年至 2032 年呈現出值得稱讚的複合年成長率。製藥公司擴大在該地區進行臨床試驗，以解決影響疾病的獨特遺傳和環境因素。此外，監管機構正在簡化核准流程，使其更有利於臨床研究。這種迅速成長的需求凸顯了該地區在推動異位性皮膚炎治療和滿足其人口醫療保健需求方面的重要性。例如，2023年12月，總部位於中國的生物製藥公司諾誠健華宣布，ICP-332治療異位性皮膚炎的II期臨床試驗取得了令人鼓舞的重要結果。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 11 章：公司簡介

BIOCYTOGEN
Charles River Laboratories
Hooke Laboratories, LLC
Imavita
Novotech
Oncodesign services
QIMA LTD
Redoxis
REPROCELL Inc.
Syneos Health

簡介目錄

Product Code: 8508

Global Atopic Dermatitis Clinical Trials Market Size will witness 11.4% CAGR between 2024 and 2032, propelled by increasing clinical trials and R&D in the field. With the prevalence of atopic dermatitis on the rise globally, pharmaceutical companies, research institutions, and healthcare providers are intensifying their efforts to develop innovative treatments and therapies. For instance, in April 2024, Corvus Pharmaceuticals, Inc., a biopharmaceutical company in the clinical stage, announced the commencement of a Phase 1 clinical trial for soquelitinib. This trial, which was randomized, placebo-controlled, and double-blind, will assess the efficacy of soquelitinib in patients with moderate to severe atopic dermatitis.

These clinical trials aim to evaluate the efficacy, safety, and tolerability of new drugs, biologics, and topical treatments for atopic dermatitis patients. Moreover, advancements in understanding the underlying mechanisms of the disease are driving the exploration of novel therapeutic targets. As a result, there's a growing need for participants, research facilities, and specialized services, amplifying the demand for atopic dermatitis clinical trials and propelling the market forward.

The overall Atopic Dermatitis Clinical Trials Industry is classified based on the study design, molecule type, phase, mode, industry, and region.

The small molecules segment will undergo rigorous development from 2024 to 2032. With the versatility and targeted approach of small molecules, pharmaceutical companies are increasingly focusing their research efforts on developing innovative therapies for atopic dermatitis. These molecules offer the potential for improved efficacy and reduced side effects compared to traditional treatments, driving interest and investment in clinical trials. As the demand for effective and safer treatments continues to grow, the exploration of small molecules in clinical trials remains a key driver in advancing the field of atopic dermatitis therapeutics.

Atopic dermatitis clinical trials market share from the observational study segment will register a notable CAGR from 2024 to 2032. These studies play a crucial role in understanding disease progression, treatment outcomes, and patient experiences in real-world settings. By complementing traditional clinical trials, observational studies provide valuable insights into the long-term effectiveness and safety of atopic dermatitis treatments. Pharmaceutical companies and researchers are increasingly recognizing the importance of observational data, driving investment and interest in conducting such studies to address the evolving needs of patients and healthcare providers in managing atopic dermatitis.

Asia Pacific atopic dermatitis clinical trials market will showcase a commendable CAGR from 2024 to 2032. With a rising prevalence of atopic dermatitis in countries across Asia Pacific, there's a growing need for effective treatments. Pharmaceutical companies are increasingly conducting clinical trials in this region to address the unique genetic and environmental factors influencing the disease. Moreover, regulatory agencies are streamlining approval processes, making it more conducive for clinical research. This burgeoning demand underscores the region's importance in advancing atopic dermatitis therapeutics and catering to the healthcare needs of its population. For instance, in December 2023, InnoCare Pharma, a biopharmaceutical company headquartered in China, announced encouraging top-line findings from the Phase II clinical trial of ICP-332 for treating atopic dermatitis.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of atopic dermatitis
  - 3.2.1.2 Growing investments for research and development activities
  - 3.2.1.3 Increasing pipeline products for atopic dermatitis
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with clinical trials
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Molecule Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Large molecules
5.3 Small molecules

Chapter 6 Market Estimates and Forecast, By Study Design, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Interventional study
6.3 Observational study
6.4 Expanded access study

Chapter 7 Market Estimates and Forecast, By Phase, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Phase I
7.3 Phase II
7.4 Phase III
7.5 Phase IV

Chapter 8 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Outsourced
8.3 In-house

Chapter 9 Market Estimates and Forecast, By Industry, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 Contract research organizations
9.3 Pharmaceutical and biotechnology companies
9.4 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa